PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Methods Mol Biol. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
PMCID: PMC2989886
NIHMSID: NIHMS227859

What Can We Learn From a Small Regulatory Membrane Protein?

Abstract

This chapter reviews the molecular biology, biochemical, and NMR methods that we used to study the structural dynamics, membrane topology and interaction of phospholamban (PLN), a small regulatory membrane protein involved in the regulation of the sarcoplasmic reticulum Ca-ATPase (SERCA). In particular, we show the progression of our research from the initial hypotheses toward understanding the molecular mechanisms of SERCA’s regulation, including the effects of PLN oligomerization and posttranslational phosphorylation. Finally, we show how the knowledge of the molecular mechanism of the structural dynamics and topology of free and bound proteins can lead to the rational design of PLN analogs for possible use in gene therapy.

Keywords: Phospholamban, SERCA, Ca-ATPase, Structural Dynamics, Topology, Membrane Proteins, NMR, PISEMA

1. Introduction

Phospholamban (PLN) is a small integral membrane protein (52 residues) localized in the sarcoplasmic reticulum (SR) membrane that regulates the flow of calcium ions into the SR lumen of cardiac muscle(1). Specifically, PLN binds to SR calcium ATPase (SERCA), the enzyme responsible for calcium re-uptake into the SR lumen. In its unphosphorylated form, PLN inhibits SERCA by reducing its affinity for calcium. Upon β-adrenergic stimulation, PLN is phosphorylated by protein kinase A at S16 with concomitant relief of SERCA inhibition and restoration of SERCA activity. These cyclic events account for the relaxation (diastolic phase) of the heart muscle and if disrupted, may evolve into heart failure(2). Due to their central role in cardiac muscle contractility, PLN and SERCA have become targets for new, alternative therapies for heart failure(3). What can be learned from the study of the structural and dynamic transitions of PLN free and when bound to SERCA? More importantly, can these studies contribute in the development of new clinical approaches to heart failure?

Much progress has been made toward understanding the molecular mechanism of SERCA within the enzymatic cycle(4, 5). Chapters 9 and 15 of this volume give exquisite portraits of the latest findings, outlining the successes of x-ray crystallography in reconstructing the structural transitions of SERCA during enzyme turnover. Undeniably, the first crystal structure of SERCA (E1-Ca2, calcium bound form) solved by Toyoshima and co-workers paved the way for the atomic level understanding of calcium translocation in the SR(6). To date, there are several crystal structures of SERCA under different experimental conditions that are allowing enzymologists to model the major conformational states of the enzyme during turnover(7). However, very few studies have been dedicated to the determination of the complexes between SERCA and its endogenous inhibitor PLN. This is probably due to the inherent dynamics of the SERCA/PLN complex that might complicate the formation of large, diffracting crystals. This hypothesis is reinforced by several fluorescence and EPR studies published by the Thomas and Squier Laboratories underscoring the dynamic nature of the SERCA/PLN complex(8-14). So far, the labs of Stokes and Young (15, 16) have produced the best images of this complex, although the resolution of the crystals does not define the interaction surface between the two proteins at the atomic level. NMR studies, on the other hand, have been focused on the structural dynamics of PLN in the unbound form. This is mainly due to the difficulties in producing isotopically labeled SERCA and analyzing its complex with PLN by solution-state NMR (Mw ~ 116 kDa).

Our laboratory, in collaboration with the Thomas laboratory, has used a combination of solution and solid-state NMR methods to map the structural dynamics, topology, and interactions between PLN and SERCA. Based on our chemical shift perturbation data from solution NMR, we have constructed an allosteric model for SERCA regulation by PLN(11, 13, 17-19). This regulatory model has been now adopted by several groups in the fields of structural biology and muscle physiology to explain the effects of naturally occurring and engineered mutations in PLN. More importantly, this model has allowed us to rationally manipulate the structural dynamics of PLN and design new mutants that are possible candidates for gene therapy in heart failure treatment.

In the following sections, we briefly review the molecular biology, biochemistry, and NMR approaches we have used to study SERCA’s regulation by looking at PLN free (monomeric and pentameric) and bound to SERCA. We show the progression of our research from our initial hypotheses on the mechanism of SERCA regulation by PLN to our initial attempts to control PLN structural dynamics to tune SERCA’s function.

2. Materials

2.1 Expression and purification of monomeric and pentameric PLN

2.1.1 Plasmid construction and mutagenesis of AFA-PLN

  1. pMal c2E maltose binding protein vector (New England Biolabs, Ipswich, MA)
  2. Oligonucleotide primers (Biomedical Genomics Center, University of MN)
  3. Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA)
  4. dNTP mix (Promega, Madison, WI)
  5. T4 DNA ligase (Promega, Madison, WI)
  6. 1x Luria-Bertani (LB) media
  7. Qiaprep Spin Miniprep Kit (Qiagen, Valencia, CA)

2.1.2 Expression of unlabeled and 15N uniformly labeled PLN

  1. BL21(DE3) strain Escherichia coli cells (Novagen, Gibbstown, NJ)
  2. 1x Luria-Bertani broth media
  3. M9 minimal media containing 12.8 g/L Na2HPO4 7H2O, 3 g/L KH2PO4, 0.5 g/L NaCl, and 1 g/L 15N-labeled NH4Cl, 2 g/L glucose, and 0.1% w/v ampicillin.
  4. 1 M IPTG (Gold Biotechnology, St. Louis, MO)
  5. Mineral cocktail: 6 mg/L CaCl2, 6 mg/L FeSO4, 1 mg/L MnCl2, 0.8 mg/L CoCl2, 0.7 mg/L ZnSO4, 0.3 mg/L CuCl2, 0.02 mg/L H3BO3, 0.25 mg/L (NH4)6MO7O24, 5 mg/L EDTA.
  6. Vitamin cocktail: 1 mg/L calcium pentothenate, 1 mg/L biotin, 1 mg/L folic acid, 1 mg/L niacinamide, 1 mg/L pyridoxal phosphate.

2.1.3 Purification of PLN

  1. Lysis buffer: 20mM PBS pH 7.3, 120 mM NaCl, 8 mM EDTA, 0.1 mM DTT, 52.6 mM glycerol, 0.5 μg/ml Pepstatin A, 0.5 μg/ml Leupeptin, 2.5 μM lysozyme, 4.5 mM Tween-20.
  2. Amylose affinity chromatography resin (New England Biolabs, Ipswich, MA).
  3. Wash buffer: 20 mM PBS pH 7.3, 120 mM NaCl.
  4. Maltose elution buffer: 46 mM maltose in 20 mM PBS pH 7.3, 120 mM NaCl, 1mM EDTA and 3.1 mM NaN3.
  5. Recombinant tobacco etch virus serine protease (Invitrogen, Carlsbad, CA or expressed and purified in our own lab) (see Note 2).
  6. Dialysis membranes with 1000 kDa molecular weight cutoff.
  7. HPLC purification: H2O with 0.1% trifluoroacetic acid and isopropanol.

2.1.4 Quantification

  1. Biorad gradient 10-15% polyacrylamide gel (Biorad, Hercules, CA).
  2. Protein standard.

2.1.5 Phosphorylation of PLN at S16 by cAMP dependent Protein Kinase A

  1. Phosphorylation buffer: 20 mM MOPS (pH 7.3), 1% β—Octylglucoside, 1 mM ATP, and 1mM MgCl2.
  2. cAMP dependent protein kinase A catalytic subunit (Sigma) or recombinant kinase as described in ref.(20).

2.2 SERCA Preparation

  1. White muscle from the back and hind legs of rabbit.
  2. Extraction buffer: 20 mM MOPS and 0.1 M KCl, pH 7.
  3. Sucrose buffer: 20 mM MOPS, 0.3 M sucrose, 1 mM NaN3.
  4. Reactive red affinity resin (Sigma).
  5. SERCA buffer: 5 mM DPC, 1 mM CaCl2, 1 mM MgCl2, 20 mM MOPS (pH 7.0), 20% glycerol, 0.25 mM DTT, and 4 mM ADP.

2.3 Functional Assays

2.3.1 SERCA PLN Co-reconstitution

  1. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-phosphoethanolamine (DOPE) (Avanti Polar Lipids, Alabaster AL).
  2. Biobeads (Biorad, Hercules, CA).
  3. β—Octylglucoside (Sigma).

2.3.2 ATPase Activity Measurements

  1. Coupled-enzyme assay mix containing 0.5 mM phosphoenol pyruvate, 2.5 mM ATP, 0.2 mM NADH, 2 IU of pyruvate kinase, 2 IU of lactate dehydrogenase, and 1-2 μg calcium ionophore (A23187).

2.3.3 31P NMR Activity Assays

  1. Couple-enzyme assay mix containing a final concentration of 10 mM dodecylphosphocholine, 1 mM MgCl2, 80 mM ATP, 20 mM MOPS (pH 7.0), and 0.2% C12E8.

2.4 NMR Spectroscopy

2.4.1 Solution state samples for titration

  1. Dodecylphosphocholine (DPC) (Avertec or Cambridge Isotope Laboratories).
  2. Solution state NMR sample buffer containing 20 mM Na2PO4, 120 mM NaCl, and 0.1% NaN3.
  3. Mini-dialysis chambers (Millipore, Billerica, MA).
  4. Guanidinium-HCl (Sigma)
  5. Dialysis buffer: 20 mM PBS and 50 mM β-mercaptoethanol.

2.4.3 Oriented Samples and ssNMR Spectroscopy

  1. 10% (w/v) sodium lauryl sulfate (SDS).
  2. DOPC and DOPE lipids.
  3. Ultra filtration concentrator (Amicon, Millipore Corporation, Bedford, MA)
  4. Glass plates, 8 × 12 mm (Marienfeld GmbH & Co, Lauda-Konigshofen, Germany).
  5. Trifluoroethanol.
  6. Extruder (Northern Lipids Inc. Burnaby, BC Canada).

3. Methods

3.1 Expression and Purification of Monomeric and Pentameric PLN

For structural studies of membrane proteins by NMR, it is necessary to find a robust expression system that allows for the purification of milligram quantities of pure protein. For this purpose, we optimized a fusion protein construct for both monomeric (cysteine null PLN with the following mutations C36A, C41F, C46A, which we refer to as AFA-PLN) and pentameric species(21).

3.1.1 Construction of PLN and Mutant PLN Expression Plasmids

To maximize the expression, all of the codons were optimized for E. coli. The nucleic acid sequence was divided into four overlapping primers and three polymerase chain reactions (PCR) were performed, with incorporation of a TEV protease cleavage site between MBP and PLN, an EcoRI restriction site at the 5′end, and a HindIII site at the 3′ end (a map of the plasmid is available from ref. (21)). Each PCR was performed with a total volume of 50 μL containing 0.06 μM of each oligonucleotide, 80 μg of parental template, 200 μM dNTP mix, and 5.0 U Pfu Turbo DNA polymerase. Each PCR reaction was carried out in an Eppendorf Master Cycler system with standard temperature cycling suggested for Pfu Turbo DNA polymerase. AFA-PLN PCR product was amplified and then ligated into EcoRI and HindIII sites on the pMal c2E vector using T4 DNA ligase (Rationale for fusion partner is described in Note 1). The ligated product was used to transform XL1-Blue competent cells with transformants selected by growth on LB/ampicillin plates. For single-site mutations of PLN, the forward and reverse primers were designed with optimized codons for E. coli three residues before and after the target residue to be mutated. PCR was performed with Pfu DNA polymerase using the protocol as described above. PCR products were then digested with Dpn-I in order to remove non-mutated methylated dsDNA, and then were transformed into XL-Blue competent cells. Constructs were amplified and extracted using the Qiaquick Spin Miniprep kit.

3.1.2. PLN Expression

E. coli BL21(DE3) cells were transformed with MBP-PLN fusion constructs. 100 ml of LB growth media with 50 μg/ml ampicillin was inoculated with a single colony and grown ~16 h at 25 °C shaking at 250 RPM to reach an OD600 of ~1.0. The growth was then diluted (1:50) into M9 media containing mineral and vitamin cocktails and grown at 37 °C to an OD600 of ~1.0. Protein expression was induced with 1 mM IPTG for 4.5 h at 37 °C. All cells were harvested by centrifugation at 6,370 × g for 20 min at 4 °C. Pellets were stored at −20 °C.

3.1.3 PLN Purification

PLN pellets (~10-15 g) were resuspended in ~400 ml of lysis buffer and agitated by blending using a Sorval Omni-Mixer 17105. Cell lysates were then sonicated on ice for 15 min using a Branson Sonifier 450 sonicator at a output setting of 4 and a duty cycle of 45%. After sonication, lysates were spun down at 45,700 × g for 20 min at 4 °C. The supernatant containing MBP/PLN fusion protein was applied to an amylose resin affinity chromatography column at 4 °C. The column was washed with 12 column volumes of wash buffer until the OD280 reached ≤ 0.05. The protein was eluted using a maltose solution, which MBP preferentially binds, separating the protein from the amylose resin. PLN was cleaved from MBP with TEV protease at 100 U/mg fusion protein at 30°C for ~5-8 h. At this point PLN can be further purified in two ways: 1) an S-100 sephacryl gel filtration column using an AKTAprime liquid chromatography system (Amersham Pharmacia Biotech), or 2) using reversed-phase HPLC. While we originally used the gel filtration method, we have abandoned this method in favor of the faster and higher resolving HPLC method as reported by Young and co-workers(22). For the HPLC method, the cleavage reaction was dialyzed against 4 L of ddH2O in a 1000 Da cutoff membrane until PLN precipitated (~12 hr). The suspension was centrifuged at 6,370 × g for 20 min at 4 °C. The supernatant containing soluble proteins (MBP, TEV protease, uncleaved fusion protein) was discarded. Pellets were solubilized in 1-2 ml of 10% (w/v) SDS and stored at 4 °C. This crude solution was purified by reversed phase HPLC using an Agilent 1100 system (Agilent Technologies, Inc. Santa Clara, CA, USA) equipped with a Vydac 208TP C8 monomeric reversed phase column (250 mm × 1.0 mm i.d. × 10 μm particle size, Grace Vydac, Hesperia, CA, USA). The mobile phases used were: A – H2O with 0.1% TFA and B – isopropanol. The column (incubated at 50 °C) was equilibrated with 10% solvent B and proteins were eluted at 2 ml/min flow rate using the following gradient: 10% to 30% solvent B in 10 min, 30% to 50% in 20 min, 50% to 70% in 30 min, and 70% to 100% in final 10 min. The column was re-equilibrated with 10% B for 10 min after each run. With these conditions the retention time for PLN was ~59 min. PLN fractions were pooled and isopropanol was evaporated under a stream of N2. The resulting suspension was lyophilized and stored at −20 °C.

3.1.4. Quantitation of Protein

Protein concentration at each purification step was determined using protein absorbance at 280 nm, or assayed with densitometry measurements of Coomassie or silver stained gels (Figure 1A). Densitometry data was collected on a Bio-Rad Molecular Imager FX using Bio-Rad Quantity One quantitation software. Recombinant protein concentrations were determined by comparison to a standard curve of 1-3 μg synthetic PLN peptides previously quantified by amino acid analysis. PLN was also identified with MALDI-MS and amino acid sequence analysis.

Figure 1
Purification and functional assays of PLN and SERCA. A) Purification gels showing expression of fusion protein (before and after induction with IPTG), selection on amylose affinity column and cleavage by TEV protease (left gel). Middle gel shows PLN monomer ...

3.1.5 Phosphorylation of PLN at S16 by PKA

HPLC-purified PLN was reconstituted to a concentration of 0.25 mg/mL for phosphorylation. 1 mg PLN was phosphorylated with 1000 U of protein kinase A catalytic subunit. Phosphorylation was confirmed using a gel-shift from a western blot with anti-pS16 PLN antibody 285 and by MALDI-TOF MS.

3.2 SERCA preparation

SERCA was extracted from rabbit skeletal muscle, purified, and tested for activity as reported previously (15, 17, 18). A solution containing 0.45 mM of SERCA, 5 mM DPC, 1 mM CaCl2, 1 mM MgCl2, 20 mM MOPS, 20% glycerol, 0.25 mM DTT, 0.4 mM ADP, pH of 7.0 was used for titration experiments (see below).

3.3 Functional Assays

3.3.1 SERCA/PLN Co-reconstitution

Lyophilized PLN protein was solubilized in 240 μL of chloroform containing 2.4 mg of lipids in a 4:1 molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). Samples were then dried by removing the organic solvent under a stream of N2 gas. The dried film of lipid and PLN was then hydrated in 120 μL of 25 mM imidazole (pH 7.0) by vortexing followed by brief (30-60 sec) water-bath sonication. The lipid/PLN vesicles were then adjusted to contain a final concentration of 20 mM imidazole (pH 7.0), 0.1 M KCl, 5 mM MgCl2, and 10% glycerol. 4.8 mg of β-octylglucoside was added, followed by 60 μg of purified SERCA with the final volume adjusted to 300 μL with buffer. Removal of the detergent was performed by incubation with 120 mg of wet Biobeads for 3 h at 25 °C. The SERCA/PLN lipid vesicles were separated from Biobeads using a gel-loading tip and micropipette and immediately assayed for function.

3.3.2 ATPase Activity Measurements

SERCA activity was assayed by an enzyme-linked assay (23) performed in a 96-well plate. Each assay was performed at 37 °C in a Thermomax microplate reader (Molecular Devices) in triplicate at different free calcium concentrations in a total volume of 175 μL. Between 1 and 3 μg of SERCA was added to the samples to start the assay, and the absorbance of NADH was monitored at 340 nm to determine the rate of ATP hydrolysis. Data was plotted in Origin 7.5 and fit using the Hill Equation (see below) to determine the shift in pKCa (Figure 1B).

3.3.3 31P NMR Activity Assays

To measure the hydrolysis of ATP by SERCA under solution NMR conditions (DPC detergent micelles), assays were performed by monitoring the inorganic phosphate 31P NMR signal. The assay mixture consisted of 6 μM SERCA, 137 μM PLN, assay mix, and concentrations of CaCl2 required to reach free Ca2+ concentration calculated based on the method of Fabiato and Fabiato(24). Upon each addition of nucleotide, eight free induction decays (FIDs) were collected, each consisting of 16 single pulse transients on 31P. Data were collected on a Varian Inova spectrometer operating at a 1H Larmor frequency of 500 MHz (Figure 1). After monitoring the rate, the inorganic phosphate signal was normalized to the known amount of DPC in the sample. This normalized amount was then plotted (V vs pCa) and fit by the Hill equation (Figure 1C).

V=Vmax[1+10n(pKCapCa)]
(1)

V is the initial ATPase rate and n is the Hill coefficient. The data were normalized to the maximal rate, Vmax, which was obtained from the fit, and then replotted to determine the shift in pKCa (Figure 1B).

3.4 NMR Spectroscopy

3.4.1 Preparation of solution NMR samples and titrations

NMR samples were prepared by dissolving isotopically labeled PLN in NMR sample buffer containing 300 mM DPC and 10% D2O to a final concentration of 0.23 mM. For the preparation of wt-PLN NMR samples (or other “difficult” samples), a slightly different procedure was used: wt-PLN was solubilized in 300 mM DPC, 20 mM PBS (pH 6.0) and 6 M guanindinum-HCl. The sample was dialyzed overnight in a mini-dialysis chamber against 1 L dialysis buffer. For the NMR titration, SERCA at a concentration of 0.51 mM was added incrementally to the PLN sample as previously reported (17). To correct for this dilution, and potential pH and salt effects, the same titration experiment was performed with SERCA buffer in the absence of enzyme. After each SERCA addition, a 1H-15N heteronuclear single quantum coherence (HSQC) experiment was collected on a Varian Inova spectrometer operating with a 1H Larmor frequency of 600 MHz at 37 °C, using an inverse detection triple-resonance and triple-axis gradient probe. The HSQC pulse program was equipped with pulsed field gradients for both coherence selection and sensitivity enhancement (25).

3.4.2. Kd Measurements by NMR

For measuring the binding constants, we assumed 1:1 binding between SERCA and PLN, and that the intensity reduction (Iretention) of the transmembrane domain residues in Figure 2C was directly related to the fraction of PLN bound to SERCA (fb). For a complete derivation of Eqn. 3 see ref. (18)(Eqns. 4-10).

fb=1Iretention
(2)

fb=Kd+[SERCA]t+[PLN]t(Kd+[SERCA]t+[PLN]t)24[SERCA]t[PLN]t2[PLN]t
(3)

The dissociation constant (Kd) was calculated using a non-linear fit to Eqn. 3.

Figure 2
Solution NMR results on AFA-PLN/SERCA complex in detergent micelles. A) The intensity retention plotted for residues 2, 3, 6, and 8 in p16 PLN (white) and PLN (black) that disappear with increasing additions of SERCA. B) The percentage of PLN in the R ...

3.4.3 Preparation of Oriented Samples and Solid-State NMR spectroscopy

PLN was reconstituted into lipid vesicles using two different preparations: 1) detergent mediated reconstitution and 2) organic solvent mediated reconstitution.

Detergent mediated reconstitution

80 mg (4/1, w/w) of DOPC/DOPE were dissolved in chloroform and thoroughly vortexed. Chloroform was evaporated under a stream of N2, after which the lipids were resuspended in 40 mL of ddH2O. The lipid suspension was sonicated on ice until small unilamellar vesicles (SUVs) formed (the suspension became transparent). After sonication, the lipids were centrifuged (6,370 × g for 10 min at 4°C) to remove larger vesicles and metal particles. PLN (~4 mg) was solubilized in 1 mL of SDS (10%, w/v) and dissolved in the lipid mixture and subjected to one freeze-thaw cycle. Samples were extensively dialyzed against ddH2O to remove the detergent and subsequently concentrated to 2 ml using an ultrafiltration device (10 kDa cutoff membrane). Approximately 100 μL of sample were transferred onto each of 20 glass plates. Samples were slowly dried at 40 °C, rehydrated to the liquid-crystalline phase and finally sealed in a rectangular glass cell.

Organic solvent mediated reconstitution

DOPC/DOPE 80 mg (4/1, w/w) were dissolved in chloroform and thoroughly mixed. PLN (~4 mg) was solubilized in 50 μL of trifluoroethanol and added to the lipid mixture. PLN (~4 mg) was solubilized in 50 μL of trifluoroethanol and added to the lipid mixture. Solvents were first evaporated under a stream of N2 and then lyophilized overnight to ensure complete removal of organic solvents. The lipid/protein mixture was resuspended in 40 mL of ddH2O and carefully vortexed. Small unilamellar vesicles were prepared by repeatedly extruding the lipid mixture through polycarbonate filters of decreasing pore size (200, 100, 50 μm) using a bench-top extruder. This SUV suspension was concentrated to 2 ml with samples dried and rehydrated as reported above. The final molar ratio of lipid/protein for all samples was ~200/1.

NMR Spectroscopy

The 2D polarization inversion spin exchange at the magic angle (PISEMA) was performed (26, 27) with TPPM decoupling during acquisition (28). A phase modulated Lee-Goldberg (PMLG) was used in the indirect dimension to decouple 1H-1H interactions and allow for the evolution of 1H−15N dipolar coupling. The initial 90° 1H pulse, cross-polarization, PMLG (1H effective field), and TPPM decoupling during acquisition were applied at ~60 kHz RF field strength. Spectra of uniformly 15N samples were acquired with 1 k scans and 30 t1 increments while selectively labeled samples required 4-12 k scans and ~8-16 increments. All experiments were performed at the National High Magnetic Field Laboratory at a 14.1 T magnetic field strength (1H frequency of 600.1 MHz) equipped with a Bruker DMX spectrometer using a low-E probe built by the RF program(29).

3.4.4 Structure Determination of monomeric and pentameric PLN using hybrid-solution and solid-state NMR method

Solution and solid-state NMR methods have been used as a complementary approach to the structure determination of small and medium size membrane proteins(30, 31). For solution NMR, the proteins are reconstituted in detergent micelles with a meticulous choice of experimental conditions, which is based on the NMR spectral features as well as preservation of SERCA function. For solid-state, we reconstitute membrane proteins in synthetic lipid bilayers, which are more amenable to enzyme function. The major advantage of solution NMR is to offer high-resolution spectra (membrane proteins up to hundreds of kDa have now been studied and assigned) and to obtain secondary and tertiary structures through NOE measurements. On the other hand, when membrane proteins are solubilized in detergent micelles, the topological information of the protein within the lipid bilayer is lost. This orientation information regarding the molecular topology can be recovered by solid-state NMR measurements using aligned samples.

Recent reports verify that the protein adopts a similar structure in both lipid bilayers and micelles; therefore, we decided to pool the information derived from these two techniques and combine the structural restraints into a unique molecular modeling protocol. The total potential energy function (ETotal) is defined as a combination of an empirical energy function (Echem) and two penalty functions that include solution (EsolNMR) and solid-state NMR (EssNMR) restraints:

ETotal=Echem+EsolNMR+EssNMR
(4)

where

Echem=Ebonds+Eangles+Etorsion+Eimproper+Evdw
(5)

EsolNMR=ENOEs+ECDIH+EHBOND+ERDC+EPRE+ECSP
(6)

EssNMR=ECSA+EDC
(7)

The energy terms of Echem are included into standard force field of XPLOR-NIH(32). EssNMR contains dipolar coupling and chemical shift anisotropy values derived from PISEMA or HETCOR experiments. As a result, the simulated annealing protocol minimizes the energy function for both distance and angular restraints as well as orientational restraints derived from solid-state NMR PISEMA experiments. Figures 3D shows the average structures from the lowest energy conformational ensembles for both the monomer and the pentamer(33).

Figure 3
Solid-state NMR spectra with overlaid ensemble PLN structures. PISEMA spectra for uniformly 15N labeled PLN monomer (A) and selectively labeled PLN pentamer (B, transmembrane domain residues; C, cytoplasmic domain residues). Note that dipolar coupling ...

3.5. CONCLUSIONS

3.5.1. Allosteric Model of SERCA Regulation by PLN

The outcomes of our investigation are summarized within the schematic in Figure 4. In agreement with both in vitro and in vivo studies, we found that PLN adopts a pentameric, L-shaped conformation both in micelles and in lipid bilayers. In particular, both solution and solid-state NMR data show that the cytoplasmic domain (which is amphipathic) interacts with the surface of the membrane mimicking environment (both for micelles and lipid bilayers), while the transmembrane domain form a tight hydrophobic bundle stapled together by a leucine-isoleucine zipper. PLN depolymerization into active monomers occurs in the presence of SERCA. In the monomeric state (prelude to the interaction with SERCA), PLN is predominantly in a resting T state with a small population in the R state. Using EPR spectroscopy, Thomas and co-workers have estimated that ~10% of PLN exists in the R state in lipid bilayers at 4 °C. In the presence of SERCA, the equilibrium is shifted toward the R state that is probably selected to bind the enzyme. While this initial detection of PLN ground (T) and excited ® states shed light inot the dynamic regulatory process of SERCA, more experiments are needed to characterize the excited states both structurally and dynamically. Our ongoing investigation is revealing a more complex equilibrium than previously anticipated. Although dynamic in nature, PLN forms a stable inhibitory complex with SERCA (Kd in DPC detergent micelles ~60 μM). This inhibition is reversed by phosphorylation at S16, which changes the conformational dynamics and results in an unwinding of the cytoplasmic helix. In the presence of SERCA, phosphorylation at S16 PLN causes a slight rearrangement within domain Ib (residues 23-30) and changes the dynamics at the binding interface. These structural dynamics affect the conformational transitions of the enzyme, and ultimately calcium translocation.

Figure 4
Allosteric model of PLN/SERCA interaction showing depolymerization of pentameric PLN into monomeric units that undergo exchange between an ordered T state and a disordered R state(s) (11,13,17-19).

3.5.2. Rational Design of PLN Mutants as Possible Candidate for Gene Therapy

A fundamental aim of structural biology is to move from understanding structure and dynamics to controlling molecular function. With this in mind, we attempted to manipulate the structural dynamics of PLN and to promote the formation of the R state through mutagenesis. Recently, we found that by mimicking the S16 phosphorylated state of PLN (i.e. enhancing the local dynamics in the hinge region) it is possible to tune the extent of SERCA inhibition(36). This work was originally inspired by in vivo studies carried out by Chien and co-workers, who demonstrated that a pseudo-phosphorylated variant of PLN can relieve SERCA inhibition and increase heart contractility, ultimately reversing the damages of myocardial infarction. We found that by changing Pro21 to Gly it is possible to generate a loss-of-function mutant with characteristics similar to S16E (pseudo-phosphorylated species tested by Chien), preserving the posttranslational control by β-adrenergic stimuli(36). This new generation of mutants possesses a residual inhibitory power that could be important in adjusting the pathophysiology of diseased hearts leading to reversal or hindrance of cardiac remodeling. We are currently working on different sites to improve the characteristic of loss-of-function mutants.

5. Notes

  1. For small membrane peptides, choice of fusion partner and cleavage protease can be crucial for successful expression and purification. Expression of small membrane peptides can induce inclusion bodies, or lead to cell death. We attempted cloning PLN with several other fusion partners and found MBP to offer the best degree of solubility and expression levels. For choosing a cleavage protease, scanning for secondary cleavage sites is also very important. For PLN, cleaving with thrombin and other proteases led to secondary cleavage. TEV has a longer recognition sequence (7 residues), making it very specific.
  2. TEV can be easily expressed in E. coli and purified using a 6x-His and Ni-NTA resin chromatography within the laboratory. A construct of TEV that is particularly effective which we use is a S219V mutant with a poly-arginine tail kindly provided to us by the Gorelick Laboratory.
  3. The method of unfolding the protein sample with guanidine HCl and refolding via dialysis used to prepare the wt-PLN solution state NMR samples described in section 3.4.1 is useful for other membrane protein NMR samples that are prone to aggregation or those which give non-uniform HSQC spectra. We have found that other “difficult” samples (such as pS16 PLN) give better spectra when prepared in this manner.

ACKNOWLEDGMENT

This work was supported by grants to G.V. from the National Institutes of Health (GM64742, HL80081, GM072701) and NJT (AHA 0515491Z). PISEMA spectra were acquired at the NHMFL, Tallahassee, FL (DMR-0084173). NMR instrumentation at the University of Minnesota High Field NMR Center was funded by the National Science Foundation (BIR-961477) and the University of Minnesota Medical School.

REFERENCES

1. Mac Lennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nature Reviews. 2003;4:566–77. [PubMed]
2. Kranias EG, Bers DM. Calcium and cardiomyopathies. Subcell Biochem. 2007;45:523–37. [PubMed]
3. Hoshijima M, Knoll R, Pashmforoush M, Chien KR. Reversal of calcium cycling defects in advanced heart failure toward molecular therapy. J Am Coll Cardiol. 2006;48:A15–23. [PubMed]
4. Inesi G, Lewis D, Ma H, Prasad A, Toyoshima C. Concerted conformational effects of Ca2+ and ATP are required for activation of sequential reactions in the Ca2+ ATPase (SERCA) catalytic cycle. Biochemistry. 2006;45:13769–78. [PMC free article] [PubMed]
5. Toyoshima C, Inesi G. Structural basis of ion pumping by Ca2+-ATPase of the sarcoplasmic reticulum. Annu Rev Biochem. 2004;73:269–92. [PubMed]
6. Toyoshima C, Nakasako M, Nomura H, Ogawa H. Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature. 2000;405:647–55. [PubMed]
7. Inesi G, Prasad AM, Pilankatta R. The Ca2+ ATPase of cardiac sarcoplasmic reticulum: Physiological role and relevance to diseases. Biochem Biophys Res Commun. 2008;369:182–7. [PMC free article] [PubMed]
8. Negash S, Chen LT, Bigelow DJ, Squier TC. Phosphorylation of phospholamban by cAMP-dependent protein kinase enhances interactions between Ca-ATPase polypeptide chains in cardiac sarcoplasmic reticulum membranes. Biochemistry. 1996;35:11247–59. [PubMed]
9. Negash S, Sun H, Yao Q, Goh SY, Bigelow DJ, Squier TC. Cytosolic domain of phospholamban remains associated with the Ca-ATPase following phosphorylation by cAMP-dependent protein kinase. Ann N Y Acad Sci. 1998;853:288–91. [PubMed]
10. Negash S, Yao Q, Sun H, Li J, Bigelow DJ, Squier TC. Phospholamban remains associated with the Ca2+- and Mg2+-dependent ATPase following phosphorylation by cAMP-dependent protein kinase. Biochem J. 2000;351:195–205. [PubMed]
11. Mueller B, Karim CB, Negrashov IV, Kutchai H, Thomas DD. Direct detection of phospholamban and sarcoplasmic reticulum Ca-ATPase interaction in membranes using fluorescence resonance energy transfer. Biochemistry. 2004;43:8754–65. [PubMed]
12. Kirby TL, Karim CB, Thomas DD. Electron paramagnetic resonance reveals a large-scale conformational change in the cytoplasmic domain of phospholamban upon binding to the sarcoplasmic reticulum Ca-ATPase. Biochemistry. 2004;43:5842–52. [PubMed]
13. Karim CB, Zhang Z, Howard EC, Torgersen KD, Thomas DD. Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA. J Mol Biol. 2006;358:1032–40. [PubMed]
14. Thomas DD, Reddy LG, Karim CB, et al. Direct spectroscopic detection of molecular dynamics and interactions of the calcium pump and phospholamban. Ann N Y Acad Sci. 1998;853:186–94. [PubMed]
15. Stokes DL, Green NM. Three-dimensional crystals of CaATPase from sarcoplasmic reticulum. Symmetry and molecular packing. Biophys J. 1990;57:1–14. [PubMed]
16. Stokes DL, Pomfret AJ, Rice WJ, Glaves JP, Young HS. Interactions between Ca2+-ATPase and the pentameric form of phospholamban in two-dimensional co-crystals. Biophys J. 2006;90:4213–23. [PubMed]
17. Zamoon J, Nitu F, Karim C, Thomas DD, Veglia G. Mapping the interaction surface of a membrane protein: unveiling the conformational switch of phospholamban in calcium pump regulation. Proc Natl Acad Sci U S A. 2005;102:4747–52. [PubMed]
18. Traaseth NJ, Thomas DD, Veglia G. Effects of Ser16 phosphorylation on the allosteric transitions of phospholamban/Ca(2+)-ATPase complex. J Mol Biol. 2006;358:1041–50. [PubMed]
19. Traaseth NJ, Ha KN, Verardi R, et al. Structural and Dynamic Basis of Phospholamban and Sarcolipin Inhibition of Ca(2+)-ATPase. Biochemistry. 2008;47:3–13. [PMC free article] [PubMed]
20. Metcalfe EE, Traaseth NJ, Veglia G. Serine 16 phosphorylation induces an order-to-disorder transition in monomeric phospholamban. Biochemistry. 2005;44:4386–96. [PubMed]
21. Buck B, Zamoon J, Kirby TL, et al. Overexpression, purification, and characterization of recombinant Ca-ATPase regulators for high-resolution solution and solid-state NMR studies. Protein Expr Purif. 2003;30:253–61. [PubMed]
22. Douglas JL, Trieber CA, Afara M, Young HS. Rapid, high-yield expression and purification of Ca2+-ATPase regulatory proteins for high-resolution structural studies. Protein Expr Purif. 2005;40:118. [PubMed]
23. Madden TD, Chapman D, Quinn PJ. Cholesterol modulates activity of calcium-dependent ATPase of the sarcoplasmic reticulum. Nature. 1979;279:538–41. [PubMed]
24. Fabiato A, Fabiato F. Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells. J Physiol (Paris) 1979;75:463–505. [PubMed]
25. Kay LE, Keifer E, Saarinen T. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. Journal of the American Chemical Society. 1992;114:10663–5.
26. Wu CH, Ramamoorthy A, Opella SJ. High-Resolution Heteronuclear Dipolar Solid-State NMR Spectroscopy. J Mag Res. 1994;109:270–2.
27. Ramamoorthy A, Wei Y, Lee D. PISEMA Solid-State NMR Spectroscopy. Ann Rep NMR Spectrosc. 2004;52:1–52.
28. Bennett AE, Rienstra CM, Auger M, Lakshmi KV, Griffin RG. Heteronuclear Decoupling in Rotating Solids. J Chem Phys. 1995;103:6951–8.
29. Vinogradov E, Madhu PK, Vega S. High Resolution Proton Solid-State NMR Spectroscopy by Phase-Modulated Lee-Goldberg Experiment. Chem Phys Lett. 1999;314:443–450.
30. Gor’kov PL, Chekmenev EY, Li C, et al. Using low-E resonators to reduce RF heating in biological samples for static solid-state NMR up to 900MHz. J Magn Reson. 2007;185:77–93. [PubMed]
31. Opella SJ, Marassi FM. Structure determination of membrane proteins by NMR spectroscopy. Chem Rev. 2004;104:3587–606. [PMC free article] [PubMed]
32. Gao FP, Cross TA. Recent developments in membrane-protein structural genomics. Genome Biol. 2005;6:244. [PMC free article] [PubMed]
33. Traaseth NH, Shi L, Verardi R, Mullen DG, Barany G, Veglia G. Structure and Topology of Monomeric Phospholamban in Lipid Membranes Determined by a Hybrid Solution and Solid-State NMR Approach. Proc Natl Acad Sci USA. 2009;106:10165–10170. [PubMed]
34. Shi L, Traaseth NH, Verardi R, Cembran A, Gao J, Veglia G. A Refinement Protocol to Determine Structure, Topology, and Depth of Insertion of Membrane Proteins Using Hybrid Solution and Solid-State NMR Restraints. J Biomol NMR. 2009;45:1195–205. [PMC free article] [PubMed]
35. Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM. The Xplor-NIH NMR molecular structure determination package. J Magn Reson. 2003;160:65–73. [PubMed]
36. Ha KN, Traaseth NJ, Verardi R, et al. Controlling the inhibition of the sarcoplasmic Ca2+-ATPase by tuning phospholamban structural dynamics. J Biol Chem. 2007;282:37205–37214. [PubMed]
37. Traaseth NJ, Verardi R, Torgersen KD, Karim CB, Thomas DD, Veglia G. Spectroscopic validation of the pentameric structure of phospholamban. Proc Natl Acad Sci U S A. 2007;104:14676–14681. [PubMed]